Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
MNPR on Nasdaq
Shares outstanding
6,743,758
Price per share
$70.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
5,520,952
Total reported value
$360,402,543
% of total 13F portfolios
0%
Share change
+1,184,607
Value change
+$74,869,431
Number of holders
72
Price from insider filings
$70.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 20% +1.6% $105,138,701 +$9,391,992 1,287,368 +9.8% JANUS HENDERSON GROUP PLC 30 Sep 2025
Monopar Therapeutics 13% $31,414,229 704,829 Hendricks Diane 09 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $43,402,756 -$4,890,637 667,632 -10% RA Capital Management, L.P. 31 Dec 2025
Adage Capital Management, L.P. 9.9% $26,706,121 599,195 Adage Capital Management, L.P. 31 Dec 2024
ASTRAZENECA PLC 7.8% $34,126,392 522,667 AstraZeneca PLC 31 Dec 2025

As of 31 Dec 2025, 72 institutional investors reported holding 5,520,952 shares of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR). This represents 82% of the company’s total 6,743,758 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 20% 1,317,410 +2.3% 0.04% $85,908,306
RA CAPITAL MANAGEMENT, L.P. 9.9% 667,207 +31% 0.45% $43,568,617
ADAGE CAPITAL PARTNERS GP, L.L.C. 9.5% 639,467 -3% 0.06% $41,757,195
Saturn V Capital Management LP 4.8% 325,701 +110% 3.9% $21,268,275
VANGUARD GROUP INC 4.4% 293,816 +41% 0% $19,186,185
BlackRock, Inc. 3.8% 254,857 +25% 0% $16,642,161
ADAR1 Capital Management, LLC 3.5% 233,908 +80% 1.1% $15,274,192
WELLINGTON MANAGEMENT GROUP LLP 3.4% 226,068 -2.3% 0% $14,762,241
Siren, L.L.C. 3.1% 212,298 0.41% $13,863,059
DEERFIELD MANAGEMENT COMPANY, L.P. 2.5% 170,558 +6.8% 0.14% $11,137,437
TCG Crossover Management, LLC 2.1% 141,915 -7.2% 0.31% $9,267,050
Polar Capital Holdings Plc 1.6% 105,750 0.03% $6,905,475
GEODE CAPITAL MANAGEMENT, LLC 1.5% 99,007 +17% 0% $6,466,445
Deep Track Capital, LP 1.4% 95,408 0.14% $6,230,142
Vivo Capital, LLC 1.3% 90,500 0% 0.38% $5,909,650
STATE STREET CORP 1.2% 83,989 +16% 0% $5,484,482
MILLENNIUM MANAGEMENT LLC 1.1% 76,674 +945% 0% $5,006,812
Bank of New York Mellon Corp 0.96% 64,857 +278% 0% $4,235,177
Alyeska Investment Group, L.P. 0.59% 40,000 +227% 0.01% $2,612,000
Driehaus Capital Management LLC 0.5% 33,715 -48% 0.01% $2,201,590
NEUBERGER BERMAN GROUP LLC 0.48% 32,547 0% $2,125,320
Balyasny Asset Management L.P. 0.47% 31,907 0% $2,083,527
NORTHERN TRUST CORP 0.45% 30,488 +14% 0% $1,990,867
MORGAN STANLEY 0.4% 26,967 +72% 0% $1,760,946
PRICE T ROWE ASSOCIATES INC /MD/ 0.34% 22,727 0% $1,485,000

Institutional Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 5,520,952 $360,402,543 +$74,869,431 $65.30 72
2025 Q3 4,336,026 $354,298,233 +$99,764,618 $81.67 55
2025 Q2 3,176,497 $113,304,454 +$10,313,028 $35.78 43
2025 Q1 2,886,019 $109,374,138 +$11,536,779 $36.41 34
2024 Q4 2,578,295 $57,125,546 +$56,777,792 $22.00 18
2024 Q3 15,707 $105,865 +$105,865 $6.74 6